Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Prognostic Factors Impacting Post-Transplant Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia: A Registry-Based Study by the Ebmt Acute Leukemia Working Party Publisher Pubmed



El Cheikh J1 ; Ngoya M2 ; Galimard JE2 ; Remenyi P3 ; Kulagin A4 ; Aljurf M5 ; Mousavi A7 ; Wu D8 ; Ozcelik T9 ; Salmenniemi U10 ; Castillallorente C11 ; Socie G12 ; Helbig G13 ; Schroeder T14 Show All Authors
Authors
  1. El Cheikh J1
  2. Ngoya M2
  3. Galimard JE2
  4. Remenyi P3
  5. Kulagin A4
  6. Aljurf M5
  7. Mousavi A7
  8. Wu D8
  9. Ozcelik T9
  10. Salmenniemi U10
  11. Castillallorente C11
  12. Socie G12
  13. Helbig G13
  14. Schroeder T14
  15. Sakellari I15
  16. Rambaldi A16
  17. Burt R17
  18. Busca A18
  19. Balsat M19
  20. Stelljes M20
  21. Brissot E21
  22. Giebel S22
  23. Peric Z23
  24. Nagler A24
  25. Bazarbachi A1
  26. Ciceri F25
  27. Mohty M21

Source: Bone Marrow Transplantation Published:2024


Abstract

T-cell acute lymphoblastic leukemia (T-ALL) predominantly affects individuals in late childhood and young adulthood. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative modality particularly in the setting of poor risk genetics and/or persistent minimal residual disease. Limited studies have directly explored the impact of patient- and transplant-related factors on post-transplant outcomes in T-ALL. Using a large dataset from the European Society for Blood and Marrow Transplantation registry, we identified 1907 adult T-ALL patients (70% male) who underwent their first allo-HSCT in first complete remission (CR1) from matched sibling donors (MSD; 45%), unrelated donors (UD; 43%) or haploidentical donors (12%) between 2010 and 2021. The median age at transplant was 33.4 years (18.1–75). The median follow up was 2.9 years. Most patients underwent total body irradiation (TBI)-based myeloablative conditioning (69%). The 2-year overall survival (OS) was 69.4%, and leukemia -free survival (LFS) was 62.1%. In multivariate analysis, advanced age at transplant negatively affected LFS (for each 10-year increment, HR = 1.11, p = 0.004), GVHD-free, relapse-free survival (GRFS) (HR = 1.06, p = 0.04), OS (HR = 1.12, p = 0.002), and non-relapse mortality (NRM) (HR = 1.23, p < 0.001). More recent years of allo-HSCT were associated with improved GFRS (For each 3-year increment, HR = 0.89, p < 0.001), OS (HR = 0.9, p = 0.02), and decreased NRM (HR = 0.82, p = 0.008). TBI improved LFS. (HR = 0.79, p = 0.02), GRFS (HR = 0.83, p = 0.04), and relapse incidence (RI) (HR = 0.65, p < 0.001). Female-to-male transplant negatively affected GRFS (HR = 1.21, p = 0.02) and OS (HR = 1.23, p = 0.048). In vivo T-cell depletion significantly improved GFRS (HR = 0.74, p < 0.001). This large study identified prognostic factors, such as age at transplant conditioning regimen, in influencing post-transplant in adult T-ALL patients undergoing allo-HSCT. Importantly, a significant improvement over time was noted. These findings hold great promise for new adapted treatment strategies and can serve as a benchmark for future studies in that setting. © The Author(s), under exclusive licence to Springer Nature Limited 2024.
Other Related Docs